<DOC>
	<DOCNO>NCT01175239</DOCNO>
	<brief_summary>X-linked severe combine immunodeficiency ( SCID-X1 ) inherit disorder result failure development immune system boys . This trial aim treat SCID-X1 patient use gene therapy replace defective gene .</brief_summary>
	<brief_title>Gene Therapy X-linked Severe Combined Immunodeficiency ( SCID-X1 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
	<criteria>1 . No HLA identical ( A , B , C , DR , DQ ) family donor HLA identical unrelated donor available within 3 month diagnosis patient whose underlying clinical problem prognosis would significantly compromise chemotherapy conditioning ( include persist pneumonitis , protract diarrhoea require parental nutrition , ongoing visceral viral infection ( herpes virus , HSV , VZV , CMV , EBV adenovirus ) , systemic BCG infection , virusinduced lymphoproliferation . 2 . Diagnosis classical SCIDX1 base immunophenotype ( absent , reduce number nonfunctional T lymphocytes ) confirm DNA sequence 3 . Parental/guardian voluntary consent 4 . Boys age 0 16</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>X-linked severe combine immunodeficiency , gene therapy</keyword>
	<keyword>Patients enrol follow diagnosis referral Great Ormond Street Immunology Service .</keyword>
</DOC>